Memorial Sloan-Kettering researchers have discovered a way that cancer cells may be able to exchange information by establishing long bridges between cells called tunneling nanotubes.

Our Annual Report features ten of the year’s most important research and clinical advances, the result of work led by physician-scientists and basic-science investigators.

Internationally recognized physician-scientist José Baselga has been named Physician-in-Chief of Memorial Hospital. He joins Memorial Sloan-Kettering from Massachusetts General Hospital.

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan-Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.

Memorial Sloan-Kettering investigators have found that some testicular cancers arising early in life may result from genetic changes that have not been inherited from either parent.

Eric Holland, Director of the Brain Tumor Center, is a neurosurgeon and researcher who studies the molecular changes that occur in glioblastoma and other brain tumors.

Memorial Sloan-Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.